Last year, an International Expert Committee advocated the use of A1C testing for the diagnosis of diabetes ([@B1]). Based on the correlation between A1C levels and risk of retinopathy in several epidemiological studies, the committee determined that an A1C value ≥6.5% should be used as the diagnostic threshold. Guided by this report, the American Diabetes Association (ADA) has approved the use of A1C as an additional criterion for diagnosing type 2 diabetes ([@B2]).

Increasing evidence, however, demonstrates a low level of agreement between a diabetes diagnosis made by A1C and one obtained using conventional criteria based on plasma glucose ([@B3][@B4][@B5][@B6]--[@B7]). As stressed by the ADA, the characterization of subjects discordantly categorized by both tests is now pending ([@B2]). The present report targeted the assessment of differences in the cardiovascular risk profiles of subjects categorized differently as having or not having diabetes with diagnostic criteria based on plasma glucose and A1C.

RESEARCH DESIGN AND METHODS
===========================

The Telde Study is a cross-sectional population-based survey conducted in Telde, a city located on the island of Gran Canaria, Canary Islands, Spain. The present study was carried out on the 964 participants (at least 30 years of age) without a previous diagnosis of diabetes. The design and conduct of the survey have been previously described ([@B8]).

A1C was determined using high-performance liquid chromatography with an HA-8140 analyzer (Menarini Diagnostics-Arkray, Kyoto, Japan) calibrated to the Japanese Diabetes Society and the Japanese Society for Clinical Chemistry (JDS/JSCC) system. Realignment to the U.S. National Glycohemoglobin Standardization Program (NGSP) values was done according to a national consensus document for the harmonization of A1C in Spain ([@B9]) using the following formula: NGSP (%) = 0.985 × JDS/JSCC (%) + 0.46. Participants were categorized according to the results of fasting and 2-h plasma glucose from a standard 75-g oral glucose tolerance test (OGTT) (diabetes or no diabetes) and A1C levels (\<6.5 or ≥6.5%) ([@B2]). The metabolic syndrome was defined according to the joint statement recently proposed by a number of professional organizations ([@B10]). Insulin resistance and pancreatic β-cell function were estimated using the homeostasis model assessment for insulin resistance (HOMA-IR) and the HOMA for β-cell, respectively.

Statistical analyses
--------------------

Age- and sex-adjusted percentages and means were obtained using logistic regression and ANCOVA, respectively. When necessary, logarithmical transformation was performed to reduce skewness, and values were expressed as geometric means. Percentages and means were compared using the likelihood ratio test and the *F* test, respectively, and homogeneity groups were determined when significant differences were found by using the corresponding linear contrasts. Multiple backward stepwise logistic regression analysis was used to investigate independent effects of associated factors with A1C ≥6.5%.

RESULTS
=======

Sixty-two subjects were diagnosed with diabetes according to the OGTT results (35 with fasting glucose ≥7 mmol/l and the remaining 27 only by 2-h glucose). Twenty-eight subjects presented an A1C value ≥6.5%, 24 of whom also had diabetes using the OGTT criteria. Thus, the diagnosis of diabetes based on an A1C ≥6.5% yielded a sensitivity of 38.7% and a specificity of 99.6%. The agreement between the glucose- and A1C-based criteria for diagnosis was moderate (κ statistic = 0.51; 95% CI \[0.387--0.641\]). [Table 1](#T1){ref-type="table"} presents the age- and sex-adjusted measures of a set of cardiovascular risk factors and indirect indicators of insulin resistance and insulin secretion according to A1C- and glucose-based diagnosis of diabetes.

###### 

Age- and sex-adjusted cardiovascular risk factors and measures of insulin resistance and insulin secretion according to diagnosis of diabetes based on OGTT and A1C

                                                            Group 1 (A1C ≥6.5%)   Group 2 (OGTT +/A1C \<6.5%)   Group 3 (OGTT −/A1C \<6.5%)   
  --------------------------------------------------------- --------------------- ----------------------------- ----------------------------- -----------------------------------------
  *n*                                                       28                    38                            898                           *P*
  Age (years)                                               54.8 (10.9)^a^        58.5 (10.9)^a^                46.4 (11.3)^b^                \<0.001
  Men/women (%)                                             67.9/32.1^a^          60.5/39.5^a^                  41.5/58.5^b^                  0.002
  BMI (kg/m^2^)                                             30.7 (0.9)^a^         28.2 (0.78)^b^                27.9 (0.16)^b^                0.009
  Waist (cm)                                                105.4 (2.2)^a^        99.0 (1.9)^b^                 96.2 (0.4)^b^                 \<0.001
  Systolic blood pressure (mmHg)                            127.3 (2.6)^a^        124.2 (2.3)^a^                117.2 (0.47)^b^               \<0.001
  Diastolic blood pressure (mmHg)                           79.4 (1.9)^a^         75.2 (1.7)^a,b^               72.8 (0.3) ^b^                0.001
  Hypertension (%)                                          34.7 (10.3)           34.0 (9.0)                    24.9 (2.0)                    0.290
  Smoking (%)                                               22.8 (11.7)           13.0 (13.4)                   24.8 (2.0)                    0.269
  Glucose (mmol/l)[\*](#TF1-1){ref-type="table-fn"}         8.12 (0.20)^a^        6.32 (0.16)^b^                4.98 (3.2)^c^                 \<0.001
  2-h glucose (mmol/l)[\*](#TF1-1){ref-type="table-fn"}     11.43 (0.75)^a^       10.4 (0.4)^a^                 5.5 (0.08)^b^                 \<0.001
  A1C (%)[\*](#TF1-1){ref-type="table-fn"}                  7.47 (0.11)^a^        5.61 (0.08)^b^                5.29 (1.5)^c^                 \<0.001
  Cholesterol (mmol/l)                                      5.35 (0.18)           5.56 (0.16)                   5.49 (0.03)                   0.646
  HDL cholesterol (mmol/l)                                  1.24 (0.06)^a^        1.41 (0.05)^b^                1.40 (0.01)^b^                0.018
  Triglycerides (mmol/l)[\*](#TF1-1){ref-type="table-fn"}   1.40 (0.13)^a^        1.40 (0.10)^a^                1.16 (0.02)^b^                0.018
  LDL cholesterol (mmol/l)                                  3.38 (0.16)           3.48 (0.14)                   3.48 (0.03)                   0.840
  CRP \>1 mg/l (%)                                          20.2 (12.0)^a^        7.1 (15.7)^a,b^               3.3 (4.7)^b^                  0.003[†](#TF1-2){ref-type="table-fn"}
  PAI-1 (ng/ml)                                             40.5 (3.35)^a^        32.2 (2.9)^a,b^               27.7 (0.6)^b^                 \<0.001
  Fibrinogen (mg/dl)                                        3.56 (0.12)^a^        3.21 (0.11)^b^                3.16 (0.02)^b^                0.005
  Von Willebrand factor (IU/l)                              126.0 (6.8)^a^        116.3 (5.9)^a,b^              106.1 (1.2)^b^                0.006
  Homocysteine (μmol/l)[\*](#TF1-1){ref-type="table-fn"}    10.9 (0.79)           10.7 (0.67)                   10.6 (0.13)                   0.916
  Metabolic syndrome (%)                                    82.1 (13.7)^a^        60.6 (9.3)^a^                 23.6 (2.2)^b^                 \<0.001[‡](#TF1-3){ref-type="table-fn"}
  Insulin (pmol/l)[\*](#TF1-1){ref-type="table-fn"}         90.38 (11.48)^a^      76.05 (7.89)^a^               48.79 (1.43)^b^               \<0.001
  HOMA-IR[\*](#TF1-1){ref-type="table-fn"}                  4.54 (0.61)^a^        2.98 (0.32)^b^                1.49 (0.06)^c^                \<0.001
  HOMA-β[\*](#TF1-1){ref-type="table-fn"}                   24.9 (3.61)           29.2 (3.12)                   23.1 (0.63)                   0.178

Values are expressed as percentages and arithmetic or geometric\* means (SE). Values followed by the same letter do not differ statistically.

†OR (95% CI) group 1 vs. group 3: 7.4 (2.7--20.4).

‡OR (95% CI) group 1 vs. group 3: 14.8 (5.0--44.0) and group 2 vs. group 3: 5.0 (2.4--10.5). CRP, C-reactive protein. PAI-1, plasminogen activator inhibitor 1.

As expected, individuals classified as nondiabetic by both diagnostic methods showed the most favorable cardiovascular risk profile. By contrast, the group meeting A1C diabetes criteria presented greater measures of BMI and waist circumference, lower values of HDL cholesterol, and higher values of fasting plasma glucose, fibrinogen, and HOMA-IR than the group fulfilling only the glucose-based criteria. Multivariate logistic regression analysis demonstrated that abdominal obesity (dichotomized with the cutoff for diagnosis of the metabolic syndrome) and 2-h plasma glucose were the only variables independently associated with an A1C value ≥6.5%.

CONCLUSIONS
===========

Several recent studies have compared A1C and OGTT for the detection of undiagnosed diabetes among the participants in different epidemiological surveys. While notable divergences have been found across ethnic groups ([@B6]), our findings are in agreement with those observed in other Caucasian-majority populations ([@B3][@B4][@B5]--[@B6]) and confirm that, considered in isolation, A1C is a very specific but too insensitive method of diagnosing diabetes.

On the other hand, although differences were not observed for other cardiovascular risk factors, such as hypertension, metabolic syndrome, or elevation of C-reactive protein, the present data show that individuals who met the A1C criterion for diabetes were characterized by greater measures of BMI and waist circumference; higher values of fasting glucose, HOMA-IR, and fibrinogen; and lower values of HDL cholesterol than individuals fulfilling only the OGTT diagnostic criteria. These results in subjects with newly diagnosed diabetes expand previous data that have related the A1C measurement to the metabolic syndrome and several markers of systemic inflammation and disturbed hemostasis among the nondiabetic population ([@B11][@B12]--[@B13]). In fact, abdominal obesity was one of the only two variables that were independently associated with an A1C value ≥6.5% in our multivariate regression model. The second variable was 2-h plasma glucose, which displaced fasting plasma glucose from the model. This finding indicates that the presence of A1C levels ≥6.5% in this subset of individuals without a previous diagnosis of diabetes depends more on postprandial plasma glucose than on basal glucose. A greater contribution of postprandial versus fasting glucose to A1C levels has been similarly observed among subjects with established diabetes and moderately increased levels of A1C ([@B14]). The particular influence of postprandial glucose, a well established cardiovascular risk factor ([@B15]), on A1C levels could reinforce the role of A1C as a potential marker of cardiovascular risk.

Accepting the limitations inherent to this small cross-sectional study, these findings could suggest the following: are individuals in the early stages of diagnosis who meet the A1C criteria for diabetes more insulin resistant and display a more unfavorable cardiovascular risk profile than those who fulfill only the OGTT-based criteria? Prospective studies focusing on this question will be needed to examine this possibility.
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